Infection with varicella zoster virus, usually during childhood, leads to the virus seeding sensory ganglia and remaining dormant \[[@CIT0001]\]. Reactivation of the virus later in life leads to herpes zoster (HZ) or shingles infection \[[@CIT0001]\], which is characterized by a unilateral vesicular and painful rash, usually in a single dermatome \[[@CIT0002]\]. Herpes zoster causes much morbidity including pain, depression, and long-term disability in the form of postherpetic neuralgia (PHN), pain that continues after the rash has subsided \[[@CIT0002], [@CIT0003]\]. More than 90% of the population has serologic evidence of varicella infection, and approximately 1 in 3 persons will develop HZ during their lifetime, leading to approximately 1 million HZ cases per year in the United States \[[@CIT0001], [@CIT0004]\]. However, the majority of treatment for HZ and PHN takes place on an outpatient basis with reported rates of HZ-related hospitalization ranging widely from 2 to 25 per 100000 person-years \[[@CIT0005]\]. The medical cost of treating HZ in the United States has been estimated to be approximately \$1.1 billion US dollars per annum \[[@CIT0006]\].

Rates of HZ infection in the general population are approximately 3 to 5 per 1000 person years, and interestingly these rates are increasing over time \[[@CIT0004], [@CIT0005]\]. The risk of HZ seems to increase with decreasing cellular immunity, which is responsible for holding the varicella virus in check \[[@CIT0007]\]. Thus, the most important risk factors for developing HZ are age and decreasing immune status \[[@CIT0001], [@CIT0005]\]. For example, studies have shown that rates of HZ infection in those 60 years of age and over is 6--8 per 1000 person years, and rise to 8--12 per 1000 person years in persons 80 years of age \[[@CIT0001], [@CIT0005]\]. Herpes zoster risk is also higher in individuals who are immunocompromised due to autoimmune diseases, solid organ or stem cell transplants, human immunodeficiency virus (HIV), and/or immunosuppressive medications that impair T-cell immunity \[[@CIT0008]\]. These medications include corticosteroids, biologics, such as tumor necrosis factor (TNF)-α blockers, or nonbiologic disease-modifying antirheumatic drugs (nbDMARDs), that is, conventional synthetic DMARDs, such as methotrexate, and targeted synthetic DMARDs, such as tofacitinib \[[@CIT0008]\]. Not only are elderly and immunocompromised individuals at higher risk for HZ, but they are also more likely to develop HZ-related complications. As such, studies have found the medical costs of treating HZ for immunocompromised patients to be nearly twice as high as other HZ patients, due to the higher rates of PHN and other complications in this group \[[@CIT0005], [@CIT0006]\].

There are multiple studies reporting the risk of HZ associated with individual immunosuppressants in patients with autoimmune diseases such as rheumatoid arthritis (RA), psoriasis, psoriatic arthritis, systemic lupus erythematous (SLE), and inflammatory bowel disease (IBD). However, the results are conflicting and statistical significance is often not detected due to the low incidence of HZ. We therefore conducted a systematic review and meta-analysis of published studies to assess the association of biologics, nbDMARDs, corticosteroids, or combinations and risk of HZ in adults with autoimmune diseases.

METHODS {#s1}
=======

This systematic review and meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@CIT0009]\] statement for randomized controlled trials (RCTs) and guidelines for the reporting of observational studies (OBS) and adverse events (AEs) \[[@CIT0010], [@CIT0011]\]. A prespecified study protocol was developed before the literature review and followed but was not registered.

Literature Search {#s2}
-----------------

We conducted a systematic literature search using MEDLINE, EMBASE, Google, Google Scholar, Cochrane, CAB Direct, CINAHL, Web of Knowledge, and PubMed for articles reporting on herpes infection in immunocompromised patients published between January 1946 and February 2016. Search terms, as both keywords and subject headings, included (*Immunosuppress\*, antirheumatic\*, methotrexate, azathioprine, 6-mercaptopurine, cyclophosphamide, cyclosporine, prednisone, corticosteroids, steroids, leflunomide, mycophenolate, tacrolimus, sirolimus, infliximab, adalimumab, etanercept, abatacept, rituximab, golimumab, certolizumab, tocilizumab, apremilast, ustekinumab, vedolizumab, biologics, mono-clonal antibodies, tumour necrosis factor (TNF) antibody, TNF, disease modifying agent, disease modifying antirheumatic drug (DMARD), DMARD, anakinra, natalizumab, tofacitinib, belimumab*) AND *(SLE, IBD, Crohn's disease, ulcerative colitis, RA, ankylosing spondylitis \[AS\], psoria\**) AND *(HZ, herpes virus, shingles*). We also conducted a manual search by reviewing the reference lists of included studies. The literature search was performed by 2 authors (E. L. and V. K.). Uncertainty and revisions were discussed with another author (F. M.).

Inclusion and Exclusion Criteria {#s3}
--------------------------------

We included studies if they compared the incidence of HZ between biologics, nbDMARDs, corticosteroids, or placebo in adults with RA, psoriasis, psoriatic arthritis, SLE, or IBD. We only included the biologicals that have been approved by the US Food and Drug Association and/or European Medicines Agency. Only RCTs and OBS, consisting of cohort studies and case-control studies, were eligible. We excluded SLE and non-SLE RCTs with fewer than 15 and 50 patients in each arm, respectively, because they were unlikely to be able to detect sufficient HZ events \[[@CIT0012]\]. Due to the lack of randomization in OBS, eligible studies were those providing adjusted or propensity score-matched associations. We excluded non-English, nonhuman, nonadult (ie, juvenile disease), and unpublished studies. Finally, although individuals with HIV, solid organ transplant, and cancer may also receive treatment with biologicals, nbDMARDS, and/or corticosteroids, we excluded these individuals because the mechanisms of the immunosuppression is distinct in each of these diseases and thus it is very likely that the background risk of HZ is very different in each of these diseases.

Data Extraction, Study Verification, and Quality Assessment {#s4}
-----------------------------------------------------------

Data were extracted independently by 2 authors (E. L. and V. K.) using a standardized abstraction form. Discrepancies were resolved through discussion with 2 other authors (F. M. and K. R.). Data extracted from the studies included the author, date of the study, baseline characteristics of patients (underlying autoimmune disease, age, sex), total number of subjects, study duration, treatment, number of patients in each medication group, duration of treatment, person-years, HZ definition, and incidence of HZ within the different medication groups.

For RCTs, where possible, we included all AEs reporting of HZ. If not recorded as such, we examined serious AEs (SAEs) of HZ, which were generally defined as HZ that is either life-threatening, causing hospitalization, or significant disability or incapacity. For the OBS, we included outcome definitions of HZ from either diagnostic records and/or adjunctive use of antiviral medications, patient or physician report. Although the primary data source was published data, for the RCT data, we searched the US National Institutes of Health trial registry and results database (<https://clinicaltrials.gov>) and contacted all principal investigators to verify the HZ definition used, whether SAE or not, and the reported numbers. We also contacted authors of OBS if any clarification was needed.

Two authors (E. L. and V. K.) independently conducted the quality assessment of the studies using the Cochrane Risk of Bias tool \[[@CIT0013]\] and the Newcastle-Ottawa quality assessment scale \[[@CIT0014]\] for RCTs and cohort/case-control studies, respectively. Points were awarded to OBS for comparability if they controlled or adjusted for age and concomitant medications because both are considered important risk factors for HZ \[[@CIT0001], [@CIT0008]\]. Discrepancies were resolved through discussion with another author (F. M. or K. R.).

Statistical Analysis {#s5}
--------------------

Because HZ is a rare event, we used the Mantel-Haenszel fixed-effects model to calculate pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of HZ associated with various immunosuppressants from the RCT data \[[@CIT0015]\]. Due to imbalances in patient numbers across some study arms, we applied a continuity correction that was inversely proportional to the relative size of the opposite arm of the study \[[@CIT0016]\]. For OBS, adjusted ORs were pooled separately using the inverse variance method. Random-effects models were used due to expected heterogeneity.

Primary analyses compared the risk of HZ of biologics (categorized by anti-TNF and non-TNF), nbDMARDs, and corticosteroids to control/placebo. For the RCTs, we either compared biologics to placebo or biologic + control therapy to control therapy. Secondary analyses compared the risk of HZ in biologics to the nbDMARDS and in combination treatments (biologics and nbDMARDS) compared with control/placebo.

We measured heterogeneity across studies using the *I*^*2*^ statistic, with higher values reflecting increasing heterogeneity \[[@CIT0016]\]. Sources of heterogeneity were assessed by subgroup analysis and by meta-regression. Specifically, subgroups were examined by disease, mean age, gender ratio, and RCT outcomes categorized both according to general AE/SAE and high risk of bias or not. We assessed publication bias by examining funnel plots and performing the Egger test for asymmetry \[[@CIT0017]\]. Pooling RCT data with many zero events can lead to mathematical instability, and although the Mantel-Haeszel fixed-effect method has been shown to perform well for this situation \[[@CIT0015]\], as a sensitivity analysis we also estimated the pooled RCT estimates using a fixed-effects Peto method and random-effects Poisson regression, which also allow for baseline study variability and any between-study heterogeneity \[[@CIT0018], [@CIT0019]\]. Stata version 12.1 (StataCorp, College Station, TX) was used for analysis. Statistical tests were 2 sided with *P* \< .05 defining statistical significance.

RESULTS {#s6}
=======

Search Results and Trial Characteristics {#s7}
----------------------------------------

The literature search and the manual search of reference lists identified 4225 studies ([Figure 1](#F1){ref-type="fig"}). Of these, the majority were excluded after reviewing the title and/or abstract. Two hundred eighty-one studies were included for a full article review and 57 studies were included after detailed assessment, corresponding to 40 RCTs (2 studies reported results of 2 RCTs in 1 paper) \[[@CIT0020]\], 16 cohort studies \[[@CIT0058]\], and 3 case-control studies \[[@CIT0073]\]. Reasons for exclusion were mainly irrelevance, study design, duplication, and lack of quantitative data about the incidence of HZ associated with individual medication or medication class.

![Study selection and included studies. \*Two papers reported results of 2 randomized control trials in 1 article. HZ, herpes zoster.](ofidis_ofw205_f0001){#F1}

The baseline characteristics of the patients included for analysis are summarized in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. In total, 20136 patients were included in the RCTs and 810939 in the OBS. The mean age of patients ranged from 25 to 75 years, and the percentage of women ranged from 9% to 87%. Study follow-up duration ranged from 6 to 104 weeks in the RCTs and 37--600 weeks in the OBS. Most studies focused on RA patients (25 of 40 RCTs and 14 of 19 observational), whereas a smaller number evaluated other autoimmune diseases. A wide variety of biologic agents, nbDMARDs, corticosteroids, and various combinations of these agents were evaluated.

###### 

Characteristics of Randomized Controlled Trials Included in the Meta-Analyses

                                                                                 Study, Year               Total Subjects^a^   Disease State^b^   Mean Age (years)   Gender (%Female)   Follow-up Duration (Weeks)^c^   Herpes Zoster Definition^d^   Treatment Group^e,f^                                                                                                                                                               N^g^                          Comparator Group(s)^e,f^                                                                                                                                                                           N^g^
  ------------------------------------------------------------------------------ ------------------------- ------------------- ------------------ ------------------ ------------------ ------------------------------- ----------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------
  1                                                                              Alarcon- Segovia 2003     230                 SLE                36                 90                 76                              AE                            B/ Abetimus 100 mg q16 wk, then alternating 8-week drug holidays and 12 weekly treatments with 50 mg                                                                               114                           Placebo                                                                                                                                                                                            116
  2                                                                              Bachelez 2015             1106                P                  44                 30                 12                              AE                            D/ Tofacitinib 5 or 10 mg BID                                                                                                                                                      662                           Placebo                                                                                                                                                                                            108
  B/ ETA 50 mg BIW                                                               336                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  3                                                                              Bejarano 2008             148                 RA                 47                 56                 56                              SAE                           B/ ADA + D/ MTX 15.5 mg/wk                                                                                                                                                         75                            Placebo + D/ MTX 16.2 mg/wk                                                                                                                                                                        73
  4                                                                              Braun 2011                566                 AS                 41                 26                 16                              AE                            B/ ETA 50 mg/wk                                                                                                                                                                    379                           D/ Sulfasalazine 2.8 g/d                                                                                                                                                                           187
  5                                                                              Bresnihan 1998            472                 RA                 53                 75                 24                              SAE                           B/ IL-1Ra (anakinra) 30 mg, 75 mg, or 150 mg × 1                                                                                                                                   351                           Placebo                                                                                                                                                                                            121
  6                                                                              Cardiel 2008              317                 SLE                --                 --                 94                              AE                            B/ Abetimus 100 mg/wk                                                                                                                                                              158                           Placebo                                                                                                                                                                                            159
  7                                                                              Chen 2013                 396                 RA                 48                 87                 24                              AE                            B/ ETA (Anbainuo) 25 mg BIW + D/ MTX 15 mg/wk                                                                                                                                      132                           D/ MTX 15 mg/wk                                                                                                                                                                                    132
  B/ ETA (Anbainuo) 25 mg BIW                                                    132                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  8                                                                              Emery 2008                542                 RA                 51                 73                 52                              SAE                           B/ ETA 50 mg/wk + D/ MTX 7.5 mg/wk                                                                                                                                                 274                           D/ MTX 7.5 mg/wk                                                                                                                                                                                   268
  9                                                                              Emery 2015                351                 RA                 47                 78                 52                              SAE                           B/ ABA 125 mg/wk SC + D/ MTX 7.5 mg/wk titrated to 15--20 mg/wk after 6--8 wks                                                                                                     119                           D/ MTX 7.5 mg/wk titrated to 15--20 mg/wk after 6--8 wk                                                                                                                                            116
  B/ ABA 125 mg/wk SC                                                            116                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  10                                                                             Fleischmann 2012          384                 RA                 53                 48                 24                              AE                            D/ Tofacitinib 1, 3, 5, 10, 15 mg BID                                                                                                                                              272                           Placebo                                                                                                                                                                                            59
  B/ ADA 40 mg/qow until wk 12, then add tofacitinib 5 mg BID until wk 24        53                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  11                                                                             Fleischmann 2013          1190                RA                 52                 83                 104                             SAE                           B/ Tocilizumab 4 mg/kg or 8 mg/ kg + D/ MTX 10--25 mg/wk                                                                                                                           798                           Placebo + D/ MTX 10--25 mg/wk                                                                                                                                                                      392
  12                                                                             Furie 2014                298                 SLE                31                 84                 52                              SAE                           B/ ABA 30 mg/kg on days 1, 15, 29, and 57, followed by ABA 10 mg/kg on days 85, 113, 141, 169, 197, 225, 253, 281, 309, and 337; or 10 mg/ kg on all infusion days + D/ MMF + C/   198                           Placebo + D/ MMF + C/                                                                                                                                                                              100
  13                                                                             Furst 2003                636                 RA                 55                 79                 24                              SAE                           B/ ADA 40 mg q2wk                                                                                                                                                                  318                           Placebo                                                                                                                                                                                            318
  14                                                                             Genovese 2008             1216                RA                 53                 82                 24                              SAE                           B/ Tocilizumab 8 mg/kg q4wk                                                                                                                                                        802                           Placebo                                                                                                                                                                                            414
  15                                                                             Kameda 2011               147                 RA                 57                 84                 52                              SAE                           B/ ETA 25 mg BIW + D/ MTX 7.4 mg/wk                                                                                                                                                76                            B/ ETA 25 mg BIW                                                                                                                                                                                   71
  16                                                                             Keystone 2004             619                 RA                 57                 75                 52                              SAE                           B/ ADA 20 mg qwk or 40 mg q2wk + D/ MTX 16.5 mg/wk                                                                                                                                 419                           Placebo + D/ MTX 16.7 mg/wk                                                                                                                                                                        200
  17                                                                             Kremer 2009               264                 RA                 51                 86                 6                               AE                            D/ Tofacitinib 5 mg, 15 mg, or 30 mg BID                                                                                                                                           199                           Placebo                                                                                                                                                                                            65
  18                                                                             Kremer 2010               609                 RA                 50                 80                 48                              SAE                           B/ Golimumab 2 mg/kg or 4 mg/ kg q12wk + D/ MTX qwk                                                                                                                                462                           B/ Golimumab 2 mg/kg or 4 mg/kg q12wk                                                                                                                                                              147
  19                                                                             Kremer 2012               507                 RA                 53                 81                 24                              AE                            D/ Tofacitinib 1, 3, 5 mg, 10, 15 mg or 20 mg BID                                                                                                                                  456                           Placebo                                                                                                                                                                                            51
  20                                                                             Kremer 2013               795                 RA                 52                 82                 52                              AE                            D/ Tofacitinib 5 mg or 10 mg BID                                                                                                                                                   636                           Placebo - Advanced to Tofacitinib at month 3; placebos that didn't respond were put on 5 mg BID Tofacitinib; at month 6, anyone not on Tofacitinib was randomly assigned to on 5 mg or 10 mg BID   159
  21                                                                             Leonardi 2008             765                 P                  45                 31                 12                              SAE                           B/ Ustekinumab 45 mg or 90 mg at wk 0, 4 then q12wk                                                                                                                                510                           Placebo                                                                                                                                                                                            255
  22                                                                             Merrill 2011              50                  SLE                45                 94                 12                              AE                            B/ Sifalimumab 0.3, 1, 3, 10 or 30 mg/kg × 1                                                                                                                                       33                            Placebo                                                                                                                                                                                            17
  23                                                                             Moutsopoulos 1978         65                  SLE                25                 81                 ≥26                             AE                            D/ CYC 0.5--3 mg/kg per day + C/ Pred \<0.5 mg/kg per day                                                                                                                          18                            C/ Pred 0.5--1.5 mg/kg per day                                                                                                                                                                     18
  D/ CYC IV 0.5 g/m^2^ q3m + C/ Pred \<0.5 mg/kg per day                         11                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  D/ AZA 1--3 mg/kg per day + C/ Pred \<0.5 mg/kg per day                        18                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  24                                                                             Nishimoto 2007            302                 RA                 53                 81                 52                              SAE                           B/ Tocilizumab 8 mg/kg q4wk                                                                                                                                                        157                           D/ MTX(85%) 7.1 mg/wk + other DMARDs                                                                                                                                                               145
  25                                                                             Papp 2015a                900                 P                  46                 29                 16                              AE                            D/ Tofacitinib 5 or 10 BID                                                                                                                                                         723                           Placebo                                                                                                                                                                                            177
  26                                                                             Papp 2015b                959                 P                  45                 33                 16                              AE                            D/ Tofacitinib 5 or 10 BID                                                                                                                                                         763                           Placebo                                                                                                                                                                                            196
  27                                                                             Rutgeerts 2005            364 (ACT1)          IBD (UC)           42                 39                 54                              AE                            B/ INX 5 mg/kg or 10 mg/kg at wk 0, 2, 6 then q8wk + C/                                                                                                                            243                           Placebo                                                                                                                                                                                            121
  28                                                                                                       364 (ACT2)                             40                 40                 30                                                            B/ INX 5 mg/kg or 10 mg/kg at week 0, 2, 6 then q8wk                                                                                                                               241                           Placebo                                                                                                                                                                                            123
  29                                                                             Sandborn 2005 (ENACT 2)   428                 IBD (CD)           37                 33                 48                              AE                            B/ Natalizumab 300 mg q4wk                                                                                                                                                         214                           Placebo                                                                                                                                                                                            214
  30                                                                             Sandborn 2009             728                 IBD (UC)           41                 40                 54                              AE                            B/ INX 5 mg/kg or 10 mg/kg at wk 0, 2, 6 then q8wk                                                                                                                                 484                           Placebo                                                                                                                                                                                            244
  31                                                                             Schiff 2008               431                 RA                 49                 84                 52                              SAE                           B/ ABA 10 mg/kg on days 1, 15, 29, then q28d up to and including day 337 + D/ MTX 16.5 mg/wk                                                                                       156                           Placebo + D/ MTX 16.6 mg/wk                                                                                                                                                                        110
  B/ INX 3 mg/kg on days 1, 15, 43, 85 and q56d thereafter + D/ MTX 16.3 mg/wk   165                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  32                                                                             Schreiber 2005            292                 IBD (CD)           36                 63                 12                              AE                            B/ CZP 100 mg or 200 mg or 400 mg at wk 0, 4, 8                                                                                                                                    219                           Placebo                                                                                                                                                                                            73
  33                                                                             Smolen 2009               461                 RA                 55                 80                 14                              SAE                           B/ Golimumab 50 mg or 100 mg q4wk                                                                                                                                                  306                           Placebo                                                                                                                                                                                            155
  34                                                                             Smolen 2013               604                 RA                 48                 81                 52                              SAE                           B/ ETA 25 or 50 mg qwk + D/ MTX 10--25 mg qwk                                                                                                                                      404                           Placebo + D/ MTX 10--25 mg/wk                                                                                                                                                                      200
  35                                                                             Takeuchi 2013             308                 RA                 52                 82                 16                              SAE                           B/ Golimumab 50 mg or 100 mg q4wk                                                                                                                                                  203                           Placebo                                                                                                                                                                                            105
  36                                                                             Tanaka 2012               261                 RA                 51                 75                 16                              AE                            B/ Golimumab 50 mg or 100 mg q4wk + D/ MTX 6--8 mg/wk                                                                                                                              173                           Placebo + D/ MTX 6--8 mg/ wk                                                                                                                                                                       88
  37                                                                             Tanaka 2015               317                 RA                 53                 83                 12                              AE                            D/ Tofacitinib 1, 3, 5, 10 or 15 mg BID                                                                                                                                            265                           Placebo                                                                                                                                                                                            52
  38                                                                             van der Heijde 2013       797                 RA                 53                 85                 24                              AE                            D/ Tofacitinib 5 or 10 BID                                                                                                                                                         716                           Placebo                                                                                                                                                                                            81
  39                                                                             van Vollenhoven 2012      717                 RA                 53                 80                 52                              AE                            D/ Tofacitinib 5 or 10 BID                                                                                                                                                         454 0--26 wk, 513 27--52 wk   Placebo 0--26 wk                                                                                                                                                                                   59
  B/ ADA 40 mg q2wk 0--52 wk                                                     204                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  40                                                                             Yamamoto 2014             230                 RA                 56                 74                 24                              SAE                           B/ CZP 400 mg at wk 0, 2, 4 then 200 mg q2wk                                                                                                                                       116                           Placebo                                                                                                                                                                                            114

Abbreviations: ABA, abatacept; ADA, adalimumab; AE, adverse event; AS, ankylosing spondylitis; AZA, azathioprine; B, biologics; BID, twice daily; BIW, twice weekly; C, corticosteroid; CD, Crohn's disease; CYC, cyclophosphamide; CZP, certolizumab; D, nonbiologics disease-modifying antirheumatic drug; ETA, etanercept; IBD, inflammatory bowel disease; IL, interleukin; INX, infliximab; IV, intravenous; LEF, leflunomide; MMF, mycophenolate mofetil; MTX, methotrexate; P, psoriasis; Pred, prednisone; q, every; qow, every other week; RA, rheumatoid arthritis; SAE, serious adverse event; SC, subcutaneous; SLE, systemic lupus erythematosus; TNF, tumor necrosis factor; UC, ulcerative colitis.

^a^Total number of individuals randomized into one of the study arms.

^b^IBD unspecified or all types; IBD (CD + UC), both Crohn's and Ulcerative Colitis in study.

^c^Maximum follow-up period (in weeks) for each subject.

^d^Herpes zoster was defined in the study as SAE and AE (or severity not specified).

^e^Types of immunosuppressive agent(s) given to each subject.

^f^Classification of agents as TNF-α inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) and non-TNF-α inhibitors (abetimus, anakinra, abatacept, tocilizumab, ustekinumab, sifalimumab, natalizumab).

^g^Total number of individuals randomized into each arm.

###### 

Characteristics of Observational Studies Included in the Meta-Analyses

                                                                                                                        Study             Study Design   Total Subjects^a^       Disease State            Mean Age (Years)                                                         Gender (% Female)                                                                                                        Mean Duration on Drug (Weeks)^b^   HZ Definition                                                                                                                      Comparator Groups^c^                              N^d^       
  --------------------------------------------------------------------------------------------------------------------- ----------------- -------------- ----------------------- ------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------ ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------- ---------- -----
  1                                                                                                                     Dreiher 2012      RC             22330                   P                        49                                                                       53                                                                                                                       506                                Record of diagnosis or prescription of antiviral                                                                                   B/ Alefacept                                      71         
  B/ Efalizumab                                                                                                         41                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  B/ ETA                                                                                                                271                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  B/ INX                                                                                                                112                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  B/ ADA                                                                                                                129                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  D/ Cyclosporine                                                                                                       94                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  D/ MTX                                                                                                                1382                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  C/                                                                                                                    4126                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Control period                                                                                                        14 746                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  2                                                                                                                     Galloway 2013     PC             15554                   RA                       57                                                                       75                                                                                                                       156                                Patient or rheumatologist report through mailed survey every 6 months or patient diary of hospital attendances and prescriptions   B/ TNFi (ETA, INX, and ADA)                       11 881     
  B/ ETA                                                                                                                4139                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ INX                                                                                                                3475                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ ADA                                                                                                                4267                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/(unspecified)                                                                                                       3673                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  3                                                                                                                     McDonald 2009     RC             20357                   RA                       63                                                                       9                                                                                                                        165                                Record of diagnosis (ICD- 9-CM code)                                                                                               C/                                                13 407     
  D/ (Mild) Hydroxycholoroquine, sulfasalazine, auranofin, injectable gold, and penicillamine                           9673                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  BD/ (Moderate) MTX, LEF, AZA, CYC, cyclosporine, and anakinra                                                         12 888                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  B/ (Severe) TNFi (ETA, INX, and ADA)                                                                                  3661                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  4                                                                                                                     Nakajima 2015     PC             7986                    RA                       58                                                                       83                                                                                                                       286                                Patient report through a survey every 6 months and then confirmed with medical chart record                                        B                                                 240        
  D/All                                                                                                                 6945                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/MTX                                                                                                                 4392                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/TAC                                                                                                                 80                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  C (1--5 mg/d, ≥5 mg/d)                                                                                                3801                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  5                                                                                                                     Pappas 2015       PC             28852                   RA                       58                                                                       76                                                                                                                       172                                Rheumalogist diagnosis of HZ                                                                                                       B/ All TNFi (ETA, ADA, INX, golimumab, and CZP)   9889       
  Non-TNFi                                                                                                              1387                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/MTX                                                                                                                 8864                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/Other                                                                                                               2795                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  C/ 0 mg                                                                                                               18 042                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C/ 1--7.4 mg/d                                                                                                        5305                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  C/ *\>7.*5 mg/d                                                                                                       1.496                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  6                                                                                                                     Osterman 2015     RC             1994                    IBD                      54                                                                       63                                                                                                                       73                                 Record of diagnosis (ICD- 9-CM code)                                                                                               B/ INX                                            912        
  B/ ADA                                                                                                                505                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  B/ INX + D/MTX or thiopurine                                                                                          381                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  B/ ADA + D/MTX or thiopurine                                                                                          196                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  7                                                                                                                     Segan 2015        RC             1870                    RA                       56                                                                       75                                                                                                                       204                                Patient report through mailed survey every 6 months                                                                                B/ ETA                                            733        
  B/ ADA                                                                                                                522                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  B/ INX                                                                                                                88                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  B/ All TNFi (ETA, ADA, INX, golimumab, and CZP)                                                                       1365                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  No TNFi use                                                                                                           297                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  8                                                                                                                     Shah 2013         RC             2717                    SLE                      49                                                                       87                                                                                                                       103                                Record of diagnosis (ICD- 9-CM code) or prescription (not specified)                                                               C/ (Oral and injectable)                          989        
  No Corticosteroids                                                                                                    1728                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  9                                                                                                                     Shalom 2015       RC             95941                   P                        46                                                                       51                                                                                                                       600                                Record of diagnosis and antiviral prescription                                                                                     B/ ETA                                            1030       
  B/ ADA                                                                                                                719                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  B/ INX                                                                                                                392                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  B/Ustekinumab                                                                                                         63                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  D/ CYC                                                                                                                148                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  D/MTX                                                                                                                 4320                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/Any TNFi + D/MTX                                                                                                    739                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Control                                                                                                               94 073                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  10                                                                                                                    Strangfeld 2009   PC             5040                    RA                       55                                                                       78                                                                                                                       108                                Adverse event (serious or nonserious) of HZ as recorded by the rheumatologist                                                      B/ ETA                                            1252       
  B/ ADA and INX                                                                                                        2014                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ TNFi (All 3 above)                                                                                                 3266                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/ (Control)                                                                                                          1774                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  C/ 0 mg                                                                                                               961                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  C/ 1--9 mg/d                                                                                                          2663                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  C/ \>10 mg/d                                                                                                          1416                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  11                                                                                                                    Veetil 2013       RC             813                     RA                       56                                                                       68%                                                                                                                      533                                Record of diagnosis (ICD-9 code) confirmed by reviewing medical record                                                             B/                                                --         
  D/ MTX                                                                                                                --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  D/ HC                                                                                                                 --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  D/ Other nonbiologic DMARDs                                                                                           --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  C/                                                                                                                    --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  12                                                                                                                    Winthrop 2013     RC             59066                   RA, IBD, P/ PA/AS        RA 58.5, IBD 40.4, P/PA/ AS 52.2                                         RA 86.3%, IBD 63.1%, P/PA/AS 61.4%                                                                                       37                                 Record of diagnosis (ICD-9 code) + antiviral prescription within 30 days                                                           B/ TNFi (INX, ETA, and ADA)                       33 324     
  D/                                                                                                                    25 742                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C/ 0 mg/d                                                                                                             28 797                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C/ 0 to \<5 mg/d                                                                                                      14 646                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C/ 5 to \<10 mg/d                                                                                                     8759                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  C/ 10 mg/d or above                                                                                                   6869                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  13                                                                                                                    Wolfe 2006        PC             10614                   RA, MSK                  61                                                                       78                                                                                                                       142                                Patient report through survey every 6 months                                                                                       B/ INX                                            3694       
  B/ ETA                                                                                                                2006                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ ADA                                                                                                                467                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  D/ LEF                                                                                                                212                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  D/ AZA                                                                                                                329                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  D/ HC                                                                                                                 2664                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/ MTX                                                                                                                6018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/ Sulfasalazine                                                                                                      701                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  D/ CYC                                                                                                                21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  C/                                                                                                                    4362                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  COX-II NSAID                                                                                                          3587                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  Non-COX II-NSAID                                                                                                      4819                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  14                                                                                                                    Yun 2015          RC             29129                   RA                       64                                                                       85                                                                                                                       38                                 Record of diagnosis (ICD-9 code) + claim for antiviral within 30 days                                                              B/ ABA                                            8389       
  B/ Rituximab                                                                                                          4311                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ Tocilizumab                                                                                                        1777                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ ADA                                                                                                                4486                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ CZP                                                                                                                1689                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ ETA                                                                                                                3554                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ Golimumab                                                                                                          1282                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  B/ INX                                                                                                                3612                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/ MTX                                                                                                                16 516                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  No MTX                                                                                                                12 613                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  No Corticosteroids                                                                                                    11 622                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C/ \<7.5 mg/d                                                                                                         12 962                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C/ \>7.5 mg/d                                                                                                         4544                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  15                                                                                                                    Zhang 2012        RC             463541                  RA + P + IBD + PA + AS   75                                                                       72                                                                                                                       104                                Record of diagnosis (ICD-9 code) + claim for antiviral within 7 days                                                               B/ TNFi (INX, ETA, ADA, and others)               --         
  B/ non-TNFi (ABA, rituximab)                                                                                          --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  D/ MTX, HC, sulfasalazine, AZA, LEF, cyclosporine, and 6-MP                                                           --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  No B/ nor D/                                                                                                          --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  With C/                                                                                                               --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Without C/                                                                                                            --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  16                                                                                                                    Zisman 2014^e^    RC             3128                    RA                       50                                                                       54                                                                                                                       221                                Record of diagnosis (ICD-9 code) + acyclovir IV/oral 5 days                                                                        B/ ETA + D/                                       158        
  No D/and no B/                                                                                                        1066                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  Cases                                             Controls   
  17                                                                                                                    Gupta 2006        RCC            2238                    IBD                      55                                                                       51                                                                                                                       234                                Record of diagnosis (Oxford Medical Information System and Read codes)                                                             D/ AZA and 6-MP                                   22         26
  D/ Mesalamine                                                                                                         96                374                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  D/ MTX                                                                                                                1                 1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  C/                                                                                                                    48                118                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  18                                                                                                                    Long 2013         RCC            13129                   IBD                      43                                                                       55                                                                                                                       130                                Record of diagnosis (ICD-9 code)                                                                                                   B/ INX, ADA, or CZP                               196        327
  C/                                                                                                                    425               728                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  D/ AZA or 6MP                                                                                                         419               806                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  B/ INX, ADA, or CZP + D/ AZA or 6MP                                                                                   --                --                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  D/ 5ASA                                                                                                               744               2563                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  19                                                                                                                    Smitten 2007      RCC            12888 (Phar- Metrics)   RA                       52                                                                       73                                                                                                                       54                                 Record of diagnosis (ICD-9 code)                                                                                                   B/ (INX, ETA, anakinra)                           32         185
  D/ (MTX, AZA, TAC, LEF, CyA, CYC, HC, SZ, gold thiomalate, aurothioglucose, auranofin, and penicillamine)             306               2018                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  C/                                                                                                                    166               503                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  B/ + D/                                                                                                               19                129                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  B/ + C/                                                                                                               12                43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  C/ + D/                                                                                                               188               660                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  B/, C/ and D/ MTX, AZA, TAC, LEF, CyA, CYC, HC, SZ, gold thiomalate, aurothioglucose, auranofin, and penicillamine)   11                49                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  No DMARD or corticosteroid                                                                                            877               7690                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  13752 (GPRD)                                                                                                          RA                61             73                      168                      Record of diagnosis (Oxford Medical Information System and Read codes)   D/ DMARD (GPRD) (MTX, AZA, TAC, LEF, CyA, CYC, HC, SZ, gold thiomalate, aurothioglucose, auranofin, and penicillamine)   273                                1633                                                                                                                                                                                            
                                                                                                                        C/                240            1061                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  C/ + D/ MTX, AZA, TAC, LEF, CyA, CYC, HC, SZ, gold thiomalate, aurothioglucose, auranofin, and penicillamine)         122               470                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  No DMARD or oral corticosteroid                                                                                       1084              8869                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

Abbreviations: 6-MP, 6-mercaptopurine; ABA, abatacept; ADA, adalimumab; AS, ankylosing spondylitis; AZA, azathioprine; B, biologics; C, corticosteroid; COX-II NSAID, cyclooxygenase II nonsteroidal anti-inflammatory drug; CYC, cyclophosphamide; CyA, cyclosporine A; CZP, certolizumab; D, nonbiologics disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; ETA, etanercept; HC, hydroxychloroquine; HZ, herpes zoster; IBD, inflammatory bowel disease; ICD-9-CM, *International Classification of Diseases, Ninth Revision, Clinical Modification*; INX, infliximab; IV, intravenous; LEF, leflunomide; MSK, musculoskeletal disease; MTX, methotrexate; P, psoriasis; PA, psoriatic arthritis; PC, prospective cohort; Pred, prednisone (corticosteroid dose was quoted as prednisone equivalents); RA, rheumatoid arthritis; RC, retrospective cohort; RCC, retrospective case control; SLE, systemic lupus erythematosus; SZ, sulfasalazine; TAC, tacrolimus; TNFi, tumor necrosis factor-α inhibitor.

^a^Total number of individuals included in the study.

^b^Mean time on immunosuppressive agent (in weeks) for each subject

^c^Types of immunosuppressive agent(s) given to each subject.

^d^Total number of individuals taking the medication (not mutually exclusive categories).

^e^Only medication groups listed compared due to overlap with the Shalom 2015 study.

Included Studies and the Risk of Bias {#s8}
-------------------------------------

Assessment of study validity revealed a potential risk of bias amongst some RCT studies ([eTable 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)), with 21 of 40 being graded as having a "high" risk of bias in any domain and only 6 RCTs rated with a low risk of bias across all domains. "Unclear" was graded for most studies due to a lack of description of the details of sequence generation and allocation concealment. Although many of the studies claimed a "double-blind" design, few of them explicitly described the parties that were blinded. The risk for incomplete outcome data was graded as high for 18 of 40 RCTs because their dropout rates exceeded 20%. In contrast, the included OBS were found at low risk of bias with scores ranging from 7 of 9 to 9 of 9, as a consequence of our inclusion criteria ([eTable 2](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1) and [3](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)).

Risk of Herpes Zoster With Biologics {#s9}
------------------------------------

Twenty-eight RCTs (n = 12272) and 6 OBS (n = 132647) reported the risk of HZ associated with biologics compared with control or no therapy ([Figure 2](#F2){ref-type="fig"}). Biologics were associated with an increased risk of HZ than control in the RCT data (OR, 1.71; 95% CI, 1.11--2.64; *I*^*2*^ = 0%) ([Figure 2a](#F2){ref-type="fig"}) and in the OBS (OR, 1.58; 95% CI, 1.39--1.81; *I*^*2*^ = 0%) ([Figure 2b](#F2){ref-type="fig"}). Stratified analysis of the RCT data, according to TNF-α inhibitors, demonstrated a greater risk of HZ for the non-TNF-α inhibitors compared with placebo (OR, 2.19; 95% CI, 1.20--4.02; *I*^*2*^ = 0%) and no statistically significant difference for the TNF-α inhibitors (OR, 1.28; 95% CI, 0.69--2.40; *I*^*2*^ = 0%) ([Figure 2a](#F2){ref-type="fig"}).

###### 

Risk of herpes zoster with biologics compared with control, pooled analysis of (a) randomized control trials and (b) observational studies. CI, confidence interval; ES, effect size; OR, odds ratio; TNF, tumor necrosis factor.
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Risk of Herpes Zoster With Nonbiological Disease-Modifying Agents {#s10}
-----------------------------------------------------------------

The pooled OR for HZ with nbDMARDS compared with control across 16 RCTs was 1.61 (95% CI, 0.84--3.10, *I*^*2*^ = 0%) ([Figure 3a](#F3){ref-type="fig"}), and across 6 OBS the pooled OR was 1.21 (95% CI, 1.15--1.28; *I*^*2*^ = 15%) ([Figure 3b](#F3){ref-type="fig"}). Only the 10 RCTs studying tofacitinib examined the impact of nbDMARD dose on HZ risk. The pooled ORs (95% CI) for 1--3 mg, 5 mg, 10 mg, and 15--30 mg twice daily (BID) of tofacitinib were 0.34 (95% CI, 0.05--2.27), 2.10 (95% CI, 0.83--5.34), 3.01 (95% CI, 1.15--7.87), and 0.63 (95% CI, 0.16--2.52), respectively ([eFigure 1](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)). However, this analysis is limited by few RCTs examining tofacitinib at 1--3 or 15--30 mg BID.

###### 

Risk of herpes zoster with nonbiological disease-modifying agents compared with control, pooled analysis of (a) randomized control trials and (b) observational studies. CI, confidence interval; ES, effect size; TNF, tumor necrosis factor.
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Risk of Herpes Zoster With Corticosteroids {#s11}
------------------------------------------

No RCTs and 15 OBS evaluated corticosteroids. The risk of HZ associated with corticosteroid use was increased significantly (OR, 1.73; 95% CI, 1.57--1.89), although there was considerable heterogeneity (*I*^*2*^ = 76%) ([Figure 4](#F4){ref-type="fig"}). Study characteristics did not explain the heterogeneity. Only 6 studies reported associations for HZ risk by corticosteroid dose. Two studies found no difference in HZ risk across dose, whereas 4 studies demonstrated increasing HZ risk with greater dose, in particular with greater than 10 mg per day ([eTable 4](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)). Because the risk of reporting bias cannot be ruled out, further analysis of corticosteroid dose was not performed.

![Risk of herpes zoster with corticosteroids compared with control, pooled analysis of observational studies. CI, confidence interval; ES, effect size.](ofidis_ofw205_f0004){#F4}

Secondary Analyses {#s12}
------------------

Pooled data from 7 RCTs (OR, 0.82; 95% CI, 0.40--1.67; *I*^*2*^ = 0%) and 5 OBS (OR, 1.06; 95% CI, 0.69--1.61; *I*^*2*^ = 71%) failed to show a significantly greater HZ risk with biologics compared with nbDMARDs ([eFigure 2](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)). Combination treatment of biologics and nbDMARD was compared with no use in 3 OBS and was associated with a greater risk of HZ (OR, 2.25; 95% CI, 1.32--3.66; *I*^*2*^ = 74%), although there was considerable heterogeneity ([eFigure 3](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)).

None of the findings varied significantly by age or sex, nor by high risk of bias or reporting of AE vs SAE for the RCT data. When evaluating the risk by disease state, there was the suggestion of reduced risks in RA patients compared with the other diseases in the RCTs but not in the OBS ([eTable 5](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)). There was also no evidence of publication bias ([eFigure 4](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1) displays the funnel plot for the RCT data comparing biologics to control therapy). Pooled effect sizes for the RCT data were generally similar when we used either the fixed-effects Peto method or random-effects Poisson regression ([eTable 6](http://ofid.oxfordjournals.org/lookup/suppl/doi:10.1093/ofid/ofw205/-/DC1)).

DISCUSSION {#s13}
==========

This is the first review to systematically examine the risks of HZ associated with immunosuppressants across various autoimmune disease states while including evidence from RCTs. Our meta-analysis indicates an elevated risk of HZ in immunosuppressed patients treated with biologics in both RCT and OBS. It is interesting to note that elevated risk of HZ was observed with non-TNF-α blocking agents but not TNF-α inhibitors. There was also evidence that treatment with corticosteroids or nbDMARDs increases the risk of HZ.

Two meta-analyses have evaluated HZ risk with immunosuppressive medications in RA patients specifically \[[@CIT0076], [@CIT0077]\]. Kourbeti et al \[[@CIT0076]\] examined opportunistic infections due to biologics from 70 RCTs (N = 21916). As a secondary analysis including 11 RCTs, they also examined varicella-zoster infection, and they found similar findings to our study, albeit not reaching statistical significance (OR, 1.51; 95% CI, 0.71--3.22). Che et al \[[@CIT0077]\] compared TNF-α blockers (N = 73510) with nbDMARDs (N = 89567) from crude numbers obtained from OBS and found an elevated risk of HZ (OR, 1.61; 95% CI, 1.16--2.23). This association is probably greater than our pooled estimates because confounding factors such as age and disease severity were not accounted for. Numerous meta-analyses have evaluated the general risk of serious infections or opportunistic infections, defined as development of a mycobacterial, fungal, or viral infection, during treatment with biologics and/or nbDMARDs. These studies have shown a clear risk of granulomatous infections, such as tuberculosis with biologics, but not necessarily for viral infections, although this may be related to lack of standardized reporting in RCTs \[[@CIT0008], [@CIT0076], [@CIT0078], [@CIT0079]\]. There were insufficient RCT data to enable us to examine HZ risk according to specific biological agents, but we did stratify our analysis according to the type of biologic and found evidence of a greater risk of HZ with non-TNF biologics. However, this finding needs to be corroborated by other investigators. Contrary to our findings, in their secondary analysis, Kourbeti et al \[[@CIT0076]\] found anti-TNF blocking agents, but not non-TNF-α blocking agents, to be associated with a significant risk of opportunistic infections (OR, 2.10; 95% CI, 1.27--3.45). The authors suggested that this may be due to heightened awareness of infectious complications in recent trials or that newer non-TNF-α blocking agents have a lower risk for opportunistic infections.

The conflicting data seen in the various reviews are likely related to whether the endpoint is risk of opportunistic infections or HZ specifically, the disease stage of the patients, given that some studies have shown a higher risk earlier on in their treatment course, as well as which particular immunosuppressive agents are being assessed \[[@CIT0078]\]. Biologics, nbDMARDs, and corticosteroids impair B-cell and T-cell immunity through different mechanisms; therefore, one can expect different degrees of immunosuppression and different effects depending on whether the pathogen is bacterial, fungal, or viral. Furthermore, all biologics do not have the same mechanism of action. For example, those considered monoclonal antibodies, such as infliximab, golimumab, adalimumab, and certolizumab, bind to both free-floating and membrane-bound TNF-α receptors \[[@CIT0080]\]; etanercept also inhibits TNF-α but is not a monoclonal antibody and binds to free TNF-α receptors only \[[@CIT0081]\]. In addition, the monoclonal antibodies can lyse other cells involved in the inflammatory process, whereas the receptor fusion protein, etanercept, lacks this capability \[[@CIT0081]\]. Non-TNF-α blocking agents are more of a mixed bag, exploiting different targets, such as antigen presenting cells (abatacept) \[[@CIT0083]\], proinflammatory cytokines, and B-cell-depleting monoclonal antibodies binding CD20 (rituximab) \[[@CIT0084]\], and therefore may have very different risk for the various microbes compared with the monoclonal TNF-α inhibitors. These differential mechanisms may be contributing to the differential risk with respect to serious infections, and further studies are needed to elucidate the specific infectious risk associated with specific agents.

Our meta-analysis found an increased HZ risk of approximately 21%--61% with nbDMARD treatment, but this only reached statistical significance in the pooled OBS. This may be due to the RCTs being underpowered to detect differences in rare AEs such as HZ \[[@CIT0079]\]. The types of nbDMARD used in the trials and clinical practice vary considerably, and our meta-analysis studies included 8 different nbDMARDs, because such we were not able to stratify results by drug, other than tofacitinib, which had enough RCTs for us to pool the results. We found that much of the increased risk associated with the nbDMARDs was related to the newer Janus kinase (JAK) inhibitor, tofacitinib, rather than the conventional DMARDs. Increased HZ with tofacitinib was also seen in Winthrop et al's \[[@CIT0085]\] meta-analysis, which evaluated data from Phase II and III studies and showed a crude incident rate of 4.4/100 person-years (95% CI, 3.8--4.9), almost 3 times the rate for TNF-α inhibitors; the risk occurred early in the treatment course rather than later. When evaluating the data according to the tofacitinib dose, we generally observed that higher doses posed an increased risk of HZ. Our literature search was completed in February 2016, and therefore we did not include 2 further studies published recently evaluating the JAK inhibitors baricitinib \[[@CIT0086]\] and ruxolitinib \[[@CIT0087]\]; however, both appear to cause an increased risk of zoster infection.

Our meta-analysis of OBS also showed an increased HZ risk with corticosteroid use. Corticosteroids impact almost all immune cells through transcriptional regulation of gene targets and inhibition of cellular proliferative responses by impairing phagocyte function and suppressing cell-mediated immunity, thereby plausibly increasing the risk of infection \[[@CIT0088]\]. A meta-analysis of 21 RCTs and 42 OBS showed that steroid therapy was not associated with a risk of infection (relative risk \[RR\], 0.97; 95% CI, 0.69--1.36) when data were pooled from the RCTs, but the OBS generated a RR of 1.67 (95% CI, 1.49--1.87), although significant heterogeneity was present \[[@CIT0089]\]. The authors concluded that the small number of events in the RCTs likely precluded seeing a clinically important increased or decreased risk. Our results also showed considerable heterogeneity and should be interpreted with caution. The heterogeneity could be due to a combination of differences in study design (eg, the inclusion of new users vs prevalent users), the ability to account for disease severity, or definitions of the control group and of HZ; however, we were not able to identify any consistent predictors. Most included studies did not examine the association between corticosteroid use and HZ as a primary hypothesis, and this could have contributed to the varying results. The dose-related increases in zoster risk reported by included studies is in keeping with guideline development reviews, which have identified that higher doses and longer treatment duration confer a greater risk of serious infection \[[@CIT0090], [@CIT0091]\].

Our study is not without limitations. We were limited by the reporting of HZ. In the RCTs, HZ was either reported as a SAE or an AE, and rather than being reported as a separate entity, it was often reported under other categories such as skin infection. We may have missed smaller studies that did not report their HZ events, and we excluded unpublished and non-English studies; however, we saw no evidence of publication bias. The studies that reported on HZ events were usually of better quality because they were larger and had structured protocols to capture rare AEs. We verified the number of HZ events in 83% of RCTs. Restricting our analysis of biologics to those verified did not affect our findings.

The minority of RCTs with substantial attrition rates are a concern. In general, they experienced greater numbers discontinuing the placebo arms due to lack of efficacy, which could have resulted in lower HZ events in the placebo arm. In contrast, studies have noted discontinuation of corticosteroid use amongst patients in biologics arms \[[@CIT0020], [@CIT0041], [@CIT0045]\], suggesting reduced HZ risk in those arms. Hence, we do not believe HZ was consistently differentially under- or overreported in treatment arms. In addition, our findings were consistent when restricted to the studies without a high risk of bias. Our pooled estimates from the RCT data were potentially mathematical unstable because they were based on few events \[[@CIT0008]\]. However, we used appropriate methods for pooling rare event data, and our estimates were very similar when other statistical approaches were applied. Unfortunately, we were unable to examine the effect of biologic dose on HZ risk because the majority of RCTs used recommended doses. We found no significant differences in HZ risk when comparing those using recommended to those using the higher end of recommended doses for biologics (results not shown). However, both the nbDMARD tofacitinib and the corticosteroids showed evidence of dose-response relationships.

Our RCT meta-analysis is strengthened by the consistent parallel evidence observed from pooled OBS that were also of high quality due to their adjustment for relevant confounders. The OBS all adjusted for age, sex, and concomitant medications, and the majority adjusted for at least a proxy for disease severity, and as such there can be considered to be limited remaining residual confounding.

Other than prompt diagnosis and initiation of antiviral therapy, prophylaxis with vaccination is an effective strategy against zoster infection. Zostavax has been demonstrated in largely healthy elderly patients of 60 years and above to decrease the risk of HZ by 51% in the 3 years postvaccination, with rates of SAE similar with placebo group \[[@CIT0092]\]; a new adjuvanted, nonlive varicella-zoster vaccine was recently tested in a Phase III clinical trial in adults 50 years or above and found to have an overall efficacy of 97% \[[@CIT0093]\]. Unfortunately, zoster vaccine is a live vaccine and is therefore not recommended to be administered to immunocompromised individuals, although a US study in which immunocompromised individuals who inadvertently received HZ vaccine did not have increased risk of HZ infection compared with controls \[[@CIT0071]\]. Given the numerous findings on the risk of HZ with biologics, and the trend seen in our study with respect to nbDMARDS and corticosteroids, we recommend following the Advisory Committee on Immunization Practices-issued guidance and offering the vaccine to patients before starting therapy \[[@CIT0094], [@CIT0095]\]. To better determine its safety profile, further efficacy trials of the nonlive HZ vaccine in patients with autoimmune disorders are also needed.

CONCLUSIONS {#s14}
===========

We demonstrated an increased risk of HZ in immunocompromized patients receiving biologics, especially non-TNF-α blockers. Increased HZ risk from corticosteroid and nbDMARD use was also observed in OBS. The use of biologics and DMARDS is now commonplace, not only in RA patients but a host of other autoimmune diseases. Our findings raise the issue of appropriate medical history and screening of patients before treatment before initiating immunosuppressants. Finally, not all biological agents are equal with respect to their potential for opportunistic infections, and postmarketing surveillance of these newer agents with different mechanisms of action than the traditional TNF-α inhibitors is vital.

Supplementary Data {#s15}
==================

Supplementary material is available at *Open Forum Infectious Diseases* online.
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